These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19673887)

  • 1. Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma.
    Ozawa S; Kato Y; Ito S; Komori R; Shiiki N; Tsukinoki K; Ozono S; Maehata Y; Taguchi T; Imagawa-Ishiguro Y; Tsukuda M; Kubota E; Hata R
    Cancer Sci; 2009 Nov; 100(11):2202-9. PubMed ID: 19673887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fasudil, a Rho kinase inhibitor, suppresses tumor growth by inducing CXCL14/BRAK in head and neck squamous cell carcinoma.
    Miyamoto C; Maehata Y; Motohashi K; Ozawa S; Ikoma T; Hidaka K; Wada-Takahashi S; Takahashi SS; Yoshino F; Yoshida A; Kubota E; Hata R; Lee MC
    Biomed Res; 2014; 35(6):381-8. PubMed ID: 25743344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of tumour-suppressing chemokine BRAK/CXCL14 reduces cell migration rate of HSC-3 tongue carcinoma cells and stimulates attachment to collagen and formation of elongated focal adhesions in vitro.
    Sato K; Ozawa S; Izukuri K; Kato Y; Hata R
    Cell Biol Int; 2010 Apr; 34(5):513-22. PubMed ID: 20067447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemokine CXCL14/BRAK transgenic mice suppress growth of carcinoma cell transplants. [corrected].
    Izukuri K; Suzuki K; Yajima N; Ozawa S; Ito S; Kubota E; Hata R
    Transgenic Res; 2010 Dec; 19(6):1109-17. PubMed ID: 20333465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
    Kalish LH; Kwong RA; Cole IE; Gallagher RM; Sutherland RL; Musgrove EA
    Clin Cancer Res; 2004 Nov; 10(22):7764-74. PubMed ID: 15570011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells.
    Ozawa S; Kato Y; Komori R; Maehata Y; Kubota E; Hata R
    Biochem Biophys Res Commun; 2006 Sep; 348(2):406-12. PubMed ID: 16884687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.
    Young NR; Liu J; Pierce C; Wei TF; Grushko T; Olopade OI; Liu W; Shen C; Seiwert TY; Cohen EE
    Mol Oncol; 2013 Jun; 7(3):359-68. PubMed ID: 23200321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer.
    Pernas FG; Allen CT; Winters ME; Yan B; Friedman J; Dabir B; Saigal K; Mundinger GS; Xu X; Morris JC; Calvo KR; Van Waes C; Chen Z
    Clin Cancer Res; 2009 Apr; 15(7):2361-72. PubMed ID: 19318490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A New Strategy to Find Targets for Anticancer Therapy: Chemokine CXCL14/BRAK Is a Multifunctional Tumor Suppressor for Head and Neck Squamous Cell Carcinoma.
    Hata R
    ISRN Otolaryngol; 2012; 2012():797619. PubMed ID: 23762619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactive oxygen species (ROS) reduce the expression of BRAK/CXCL14 in human head and neck squamous cell carcinoma cells.
    Maehata Y; Ozawa S; Kobayashi K; Kato Y; Yoshino F; Miyamoto C; Izukuri K; Kubota E; Hata R; Lee MC
    Free Radic Res; 2010 Aug; 44(8):913-24. PubMed ID: 20815772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
    Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
    Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of a chemokine BRAK/CXCL14 in oral floor carcinoma cells reduces the settlement rate of the cells and suppresses their proliferation in vivo.
    Ito S; Ozawa S; Ikoma T; Yajima N; Kiyono T; Hata R
    Biomed Res; 2010 Jun; 31(3):199-206. PubMed ID: 20622470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells.
    Yang Z; Bagheri-Yarmand R; Wang RA; Adam L; Papadimitrakopoulou VV; Clayman GL; El-Naggar A; Lotan R; Barnes CJ; Hong WK; Kumar R
    Clin Cancer Res; 2004 Jan; 10(2):658-67. PubMed ID: 14760089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
    Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
    Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
    Secades P; de Santa-María IS; Merlo A; Suarez C; Chiara MD
    Head Neck; 2015 Aug; 37(8):1150-62. PubMed ID: 24798801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional characterization of proximal promoter of gene for human BRAK/CXCL14, a tumor-suppressing chemokine.
    Komori R; Ozawa S; Kato Y; Shinji H; Kimoto S; Hata R
    Biomed Res; 2010 Apr; 31(2):123-31. PubMed ID: 20460740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib.
    Timpson P; Wilson AS; Lehrbach GM; Sutherland RL; Musgrove EA; Daly RJ
    Cancer Res; 2007 Oct; 67(19):9304-14. PubMed ID: 17909038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric modulation by protein kinase Cε leads to modified responses of EGF receptor towards tyrosine kinase inhibitors.
    Weisheit S; Liebmann C
    Cell Signal; 2012 Feb; 24(2):422-434. PubMed ID: 21964064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway.
    Maseki S; Ijichi K; Tanaka H; Fujii M; Hasegawa Y; Ogawa T; Murakami S; Kondo E; Nakanishi H
    Br J Cancer; 2012 Mar; 106(6):1196-204. PubMed ID: 22315058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.